Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

20021,621 citationsletterbronze Open Access

Authors

Good health and well-being

Published in: Cancer Cell

Volume 2, Issue 2, pp. 117-125

Field-Weighted Citation Impact: 33.45